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Background: Patients with brain metastases from lung cancer have poor prognoses and short survival time, and
they are often excluded from clinical trials. Whole-cranial irradiation is considered to be the standard treatment, but
its efficacy is not satisfactory. The purpose of this phase II clinical trial was to evaluate the preliminary efficacy and
safety of the treatment of whole-brain irradiation plus three-dimensional conformal boost combined with
concurrent topotecan for the patients with brain metastases from lung cancer.
Methods: Patients with brain metastasis from lung cancer received concurrent chemotherapy and radiotherapy:
conventional fractionated whole-brain irradiation, 2 fields/time, 1 fraction/day, 2 Gy/fraction, 5 times/week, and DT
40 Gy/20 fractions; for the patients with≤ 3 lesions with diameter≥ 2 cm, a three-dimensional (3-D) conformal localised
boost was given to increase the dosage to 56–60 Gy; and during radiotherapy, concurrent chemotherapy with
topotecan was given (the chemoradiotherapy group, CRT). The patients with brain metastasis from lung cancer during
the same period who received radiotherapy only were selected as the controls (the radiotherapy-alone group, RT).
Results: From March 2009 to March 2012, both 38 patients were enrolled into two groups. The median
progression-free survival(PFS) time , the 1- and 2-year PFS rates of CRT group and RT group were 6 months, 42.8%,
21.6% and 3 months, 11.6%, 8.7% (χ2 = 6.02, p = 0.014), respectively. The 1- and 2-year intracranial lesion control
rates of CRT and RT were 75.9% , 65.2% and 41.6% , 31.2% (χ2 = 3.892, p = 0.049), respectively. The 1- and 2-year
overall survival rates (OS) of CRT and RT were 50.8% , 37.9% and 40.4% , 16.5% (χ2 = 1.811, p = 0.178), respectively.
The major side effects were myelosuppression and digestive toxicities, but no differences were observed between
the two groups.
Conclusion: Compared with radiotherapy alone, whole-brain irradiation plus 3-D conformal boost irradiation and
concurrent topotecan chemotherapy significantly improved the PFS rate and the intracranial lesion control rate of
patients with brain metastases from lung cancer, and no significant increases in side effects were observed. Based
on these results, this treatment method is recommended for phase III clinical trial.
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With the increase in lung cancer incidence year-by-year
and prolonged survival, the incidence of brain metastases
from lung cancer has also been rising, accounting for ap-
proximately 45% of intracranial metastatic carcinoma [1].
The prognosis for patients with brain metastases is ex-
tremely poor; the natural disease duration is less than
3 months [2]. Radiation therapy remains the primary treat-
ment for patients with brain metastases. Specifically,
whole-brain irradiation alone is the most commonly used
method to treat brain metastases from lung cancer [3-5],
and it can increase patient survival by up to 3–6 months
[6,7]. However, half of the patients experience local con-
trol failure or recurrence [8,9]. Thus, the local control of
brain metastases is a key factor for prolonging patient sur-
vival and improving their quality of life. With the increasing
application of precise three-dimensional (3-D) conformal
radiotherapy, it has been reported that, in the case of large
tumours, precise radiotherapy after whole-brain radiother-
apy improves the local control rate and effectively alleviates
the central nervous system symptoms [10,11].Figure 1 The synthesis scheme demonstrated the final effects of the
residual lesion. The orange line was 60 Gy to PTV, while the blue line wasMetastasis of lung cancer to the brain indicates an ad-
vanced stage of disease. The combination of cranial radio-
therapy and systemic chemotherapy should theoretically
strengthen local control and reduce tumour metastases,
thereby improving survival [12]. Chemotherapy drugs that
can pass through the blood–brain barrier and sensitise
tumour cells to radiation may effectively treat brain metas-
tases from lung cancer.
The semi-synthetic camptothecin derivative topotecan in-
hibits topoisomerase I and can pass through the blood–brain
barrier and exert a radiosensitising effect [13]. It was reported
that the combined treatment of topotecan and whole-brain
irradiation for patients with brain metastases from lung can-
cer improved the local control rate of brain metastases and
also demonstrated a trend of improvement in survival
[14,15]. To our knowledge, there have been no reports of
whole-brain irradiation plus 3-D conformal boost combined
with concurrent topotecan chemotherapy. We previously
conducted a phase I clinical trial of radiotherapy combined
with topotecan for the treatment of brain metastases from
lung cancer and determined the maximum tolerated dosewhole cranial irradiation plus late course boost irradiation to
40 Gy to the whole cranum.














KPS score range 60–90 60–90 0.831 0.406
Weight loss 0.482 0.487
≥5% 11 10
<5% 12 13
Histological type 0.502 0.479
Small cell lung cancer 16 13
Non-small cell lung cancer 22 25
Brain metastasis numbers 0.220 0.896
1 12 11
2 ~ 3 7 6
>3 19 21
Diameter of brain metastasis 0.3 ~ 3.8 0.5 ~ 3.5 0.413 0.680
Mean diameter(cm) 1.95 1.94 0.965 0.335
Accompanied with
extracranial metastasis
14 16 0.220 0.639
Brain metastasis only 24 22
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evaluate the safety and efficacy of the combined regimen.
Methods
Eligibility
The inclusion criteria in this study were as follows: patients
with brain metastases from lung cancer which were patho-
logically or cytologically confirmed; previously untreated
patients or patients with brain metastases after treatment
for extracranial tumour; the metastasis not in the brainstem
based on the cranial MRI examination performed before
treatment; 18–70 years old; Karnofsky performance status
(KPS) score ≥ 60; normal blood, liver, and kidney tests; no
chemotherapy in the previous month; no history of cranial
radiotherapy or surgery; and expected survival≥ 3 months.
The exclusion criteria were as follows: pregnant or breast-
feeding women, second primary malignancy, severe pulmon-
ary infection, combined psychiatric disorder, or other
diseases requiring hospitalisation. All patients provided writ-
ten informed consent. This study was approved by the Hebei
University Ethics Committee, met the standards of human
clinical trial, and complied with the provisions of the Declar-
ation of Helsinki in 1975 (including the 2000 Revision).
Baseline assessment
Baseline assessment included taking a detailed medical his-
tory, comprehensive physical examination, head magnetic
resonance imaging (MRI) scan with contract, chest and ab-
domen computed tomography (CT) scan, ECT bone scan if
clinically suggested, electrocardiogram, and routine blood
and comprehensive metabolic panel examinations. All tests
were completed two weeks before the treatment.
Treatment plan
The patients in the concurrent chemoradiotherapy group
(CRT group) received whole-brain irradiation with 3-D
conformal boost combined with concurrent topotecan
chemotherapy. The patients who received the same radio-
therapy regimen without concurrent chemotherapy during
the same period were selected as the control group (radio-
therapy-alone group, RT group).
Radiotherapy
Elekta accelerators (Precise linear accelerator, 6MV-X-ray)
were employed in this study. Nucletron Plato Patient Se-
lection system v3.4.0 software was used to optimise radi-
ation treatment planning. Radiotherapy was performed
with multi-leaf collimator whole-brain irradiation, 2 fields/
time/day, 5 days/week, DT40Gy/20 times. All patients re-
ceived head MRI scan with contract after the dosage of
DT40Gy. For patients with ≤3 intracranial metastases with
lesion diameters ≥ 2 cm, CT simulation with contrast was
performed. The MRI and CT image fusion was used for
target delineation. The gross tumor volume (GTV) wasdefined as the intracranial residual lesions, and the plan-
ning target volume (PTV) was defined as the GTV en-
larged by a margin of 3 mm. Irradiation was boost with
three-dimensional conformal radiotherapy technology.
According to the organs at risk, the total dose for PTV
was up to 56–60Gy (as shown in Figure 1).
Concurrent chemotherapy
Topotecan was administered at 1.75 mg/m2 by phleboclysis
once a week on the first day of radiotherapy and given 4–6
times over 4–6 weeks [16].
Evaluation of the efficacy and side effects
One month after radiotherapy was completed, cranial
MRI and chest and abdominal CT were performed to
evaluate treatment efficacy according to RESICT1.1 stan-
dards [17]. Side effects were evaluated according to the
Common Terminology Criteria for Adverse Events v3.0
(CTCAE 3.0).
Follow up
All cases were followed up with outpatient or inpatient
examinations and telephone interviews. The follow-up
was conducted monthly for the first 3 months, then at
6 months, and once every 6 months subsequently. As
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both groups.
Trial design and study endpoints
This was a prospective phase II clinical study to evalu-
ate the preliminary efficacy and safety of the concurrent
chemoradiotherapy. The control group received the
same radiotherapy regimen without concurrent chemo-
therapy during the same period of time. SPSS16.0 statis-
tical software (SPSS Inc., Chicago, IL, USA) was used
for statistical analyses. The outcome ratios were used
for χ2 tests, t-tests or rank-sum tests were applied to
compare group means, survival rates and the control
rates of intra- and extracranial lesions were calculated
using the Kaplan-Meier method, and significance was de-
termined with Log-Rank tests. For all analyses, p < 0.05
was considered statistically significant.
The primary endpoint of this study was progression-
free survival (PFS), and the secondary endpoints were
overall survival (OS), intra- and extracranial lesion con-
trol rates, total efficiency, and side effects.
Results
Enrollment
From March 2009 to March 2012, 38 patients were
prospectively enrolled in CRT group, and 38 patientsFigure 2 The median PFS time and 1-and 2-year PFS rates in CRT gro
11.6%, 8.7% (χ2 = 6.02, p = 0.014), respectively.who received radiotherapy alone during the same
period of time were selected as the control group (RT
group). Together, the study population included 47
males and 29 females aged from 36 to 70 years old, and
the median ages of the concurrent and radiotherapy-
alone groups were 59 and 60.5 years old, respectively.
The concurrent group included 15 cases of small cell
lung cancer (SCLC) and 23 cases of non-small cell lung
cancer (NSCLC). The radiotherapy-alone group was
comprised of 13 cases of SCLC and 25 cases of NSCLC.
In the concurrent and radiotherapy-alone groups,
14 and 16 cases showed concomitant metastases in
other organs, respectively. There were no significant
differences in clinical data between the two groups
(Table 1).
Treatment completion
In CRT group, 17 patients underwent 3-D conformal
boost irradiation. One patient showed a low platelet
count after 36-Gy whole-brain irradiation with concur-
rent chemotherapy for 3 weeks, and chemotherapy
was stopped. The remaining patients completed four
rounds of concurrent chemotherapy and underwent
conformal boost. In RT group, all patients completed
the radiotherapy, and 15 patients received conformal
boost.up and RT group were 6 months, 42.8%, 21.6% and 3 months,
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In CRT group, 9 cases showed complete response (CR), 24
cases showed partial response (PR), and 5 cases exhibited
stable disease (SD), for a total response rate (CR + PR) of
86.84%. In RT group, there were 5 cases of CR, 23 cases of
PR, and 10 cases of SD, for a total response rate (CR + PR)
of 73.68%. The response rate of CRT group was higher
than that of RT group, but the difference was not statisti-
cally significant (χ2 = 2.077, p = 0.149).
PFS
The median PFS time and 1-and 2-year PFS rates in
CRT group and RT group were 6 months, 42.8%, 21.6%
and 3 months, 11.6%, 8.7% (χ2 = 6.02, p = 0.014), respect-
ively. The PFS of CRT group was significantly longer
than that of RT group (Figure 2).
Overall survival rate
The median survival time (MST), the 1- and 2-year sur-
vival rates were 13 months, 50.8% and 37.9% for CRT
group and 10 months, 40. 4% and 16.50% for RT group
(χ2 = 1.811, p = 0.178), respectively. Survival time in CRT
group was longer than that in RT group, but the differ-
ence was not statistically significant (Figure 3).Figure 3 The median survival time (MST), the 1- and 2-year survival r
10 months, 40.4% and 16.50% for RT group (χ2 = 1.811, p = 0.178), reIntracranial lesion control rate
The median intracranial lesion local control time of CRT
group had not yet been reached, and the median intracra-
nial lesion local control time of RT group was 11 months.
The 1- and 2-year intracranial lesion local control rates
were 75.9% and 65.2% for CRT group and 41.6% and
31.2% for RT group. The intracranial lesion control rate of
CRT group was significantly longer than that of RT group
(χ2 = 3.892, p = 0.049), as shown in Figure 4.
Extracranial lesion control rate
The median extracranial lesion control times and the 1-
and 2-year extracranial lesion control rates of CRT and RT
groups were 8 months, 47.8%, and 28.7% and 5 months,
32.5%, and 24.4% (χ2 = 0.610, p = 0.435), respectively.
There was no significant difference in the extracranial le-
sion control rate between the two groups (Figure 5).
Histological type on survival
Among the patients in both groups, there were 17 cases
of patients with SCLC in CRT group and 13 cases in RT
group. The MST and the 1- and 2-year survival rates of
CRT group and RT group were 28 months, 72.7%, 58.2%
and 15 months, 63.6%, 27.3% (χ2 = 0.884, p = 0.347),ates were 13 months, 50.8% and 37.9% for CRT group and
spectively.
Figure 4 The median intracranial lesion local control time of CRT group had not yet been reached, and that of RT group was
11 months. The 1- and 2-year intracranial lesion local control rates were 75.9% and 65.2% for CRT group and 41.6% and 31.2% for RT group.
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CRT group and 25 cases in RT group. The MST and the 1-
and 2-year survival rates of the two groups were 10 months,
33.8%, 16.9% and 8 months, 26.3%, 9.9%, respectively, with
no statistically significant difference (χ2 = 0.667, p = 0.414)
between the two groups (Figure 7).
Side effects
The side effects in both groups were mainly bone mar-
row suppression and gastrointestinal toxicities. The inci-
dence of side effects in CRT group was slightly higher
than that in RT group. The bone marrow suppression
rates in the two groups were 68.42% and 50%, respect-
ively, and gastrointestinal toxicities occurred in 63.15%
and 44.73%, respectively. There was no statistically sig-
nificant difference for either type. The side effects expe-
rienced in the two groups were mostly Grade I–II, with
a lower incidence of Grade III side effects, and no side
effect with degree IV or above occurred (Table 2).
Cancer related death
Through the last follow-up, 22 patients in CRT group died
and 16 survived. The causes of death were as follows:
5 cases died of intracranial recurrence alone, 4 cases died of
intracranial recurrence and multiple extracranial metasta-
ses, 12 cases died of extracranial metastases alone(including 6 cases of systemic multiple metastases, 4 cases
of bone metastases, and 2 cases with liver metastases), and
1 case died as a result of lung tumour recurrence (died of
massive haemoptysis). The causes of death in CRT group
were mostly extracranial metastases, accounting for 54.5%
(12/22). In RT group, 26 cases died and 12 cases survived; 9
cases died of intracranial recurrence alone, 3 cases died of
intracranial recurrence and multiple extracranial metasta-
ses, 13 cases died of extracranial metastases alone (includ-
ing 5 cases of systemic multiple metastases, 5 cases of bone
metastases, 2 cases of liver metastases, and 1 case of lung
metastases), and 1 patient died of massive haemoptysis due
to lung tumour recurrence. The causes of death in RT
group were mainly extracranial metastases, accounting for
50.0% (13/26). CRT failed to significantly reduce mortality
due to extracranial metastasis (χ2 = 0.099, p = 0.753).Discussion
Whole-brain radiotherapy is currently the standard treat-
ment for brain metastasis from lung cancer and can in-
crease patient survival up to 3–6 months [6,7]. However,
the rate of complete remission is low, with 30–50% of pa-
tient deaths caused by uncontrolled and recurrent intra-
cranial lesions [8,9]. The possible reasons are insufficient
dose for local tumour during whole-brain irradiation and
Figure 5 The 1- and 2-year extracranial lesion control rates of CRT and RT groups were 8 months, 47.8%, and 28.7% and 5 months,
32.5%, and 24.4% (χ2 = 0.610, p = 0.435), respectively.
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blood–brain barrier.
Three-dimensional conformal radiotherapy is a newly
developed radiation therapy technology that can maximise
the radiotherapy dose to tumour but not normal tissues
and can increase treatment efficacy [18]. The results of
RTOG9508 indicated that, for the patients with 1–3 brain
metastases, whole-brain irradiation plus boost precision
radiotherapy significantly improved the efficacy and local
control rate compared with whole-brain irradiation alone,
with 1-year local control rates of 82% and 71%, respect-
ively. Efficacy was even better for patients with a single
brain metastasis. Further analysis found that, for patients
with localised lesions ≥ 2 cm and ≤ 3 metastases, whole-
brain radiotherapy plus localised boost irradiation showed
good efficacy [10]. Similarly, Casanova et al. [19] found
that whole-brain radiotherapy plus localised boost irradi-
ation achieved good efficacy for patients with 1–3 brain
metastases from lung cancer, with a 1-year local control
rate of 75.2%. Univariate analysis revealed that the local
dose was positively correlated to the survival.
Stafinski et al. [20] reported that whole-brain radiother-
apy plus boost precision irradiation for brain metastases
(no other distant metastasis) from lung cancer had an ef-
fective rate of 91%, which was significantly higher thanthat of the radiotherapy-alone group of 62%. The 2-year
local control rate of 51% and the 2-year survival rate of
23% were also significantly higher than those of the
whole-brain radiotherapy-alone group. For patients with
other concomitant extracranial metastases, whole-brain ir-
radiation plus boost precision radiotherapy only improved
local control; it did not affect survival, suggesting the im-
portance of systemic concurrent chemotherapy for con-
trolling extracranial metastases.
A previous study found that chemotherapy concurrent
with whole-brain irradiation may improve treatment effi-
cacy [12]. Topotecan is a semi-synthetic camptothecin de-
rivative. As an inhibitor of topoisomerase I, topotecan can
pass through the blood–brain barrier and exerts a
radiosensitising effect, with 33–63% efficacy for brain me-
tastasis tumour [13,21-23]. Combining whole-brain irradi-
ation with a maximum daily tolerated dose of topotecan at
0.4–1.0 mg/m2/d [14,15,24] can improve the local control
rate of brain metastases, and patients can tolerate it, with
myelosuppression as the main side effects. Hedde et al.
[15] applied topotecan combined with whole-brain radio-
therapy in patients with brain metastases from lung or
breast cancer and achieved a treatment efficacy of 72%.
Mirmiran et al. [24] also applied topotecan combined with
whole-brain radiation therapy for lung cancer patients
Figure 6 For small cell lung cancer, the MST and the 1- and 2-year survival rates of CRT group and RT group were 28 months, 72.7%,
58.2% and 15 months, 63.6%, 27.3% (χ2 = 0.884, p = 0.347), respectively.
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ation of 30 Gy/10 times, and the median PFS time of
60 days and the MST of 102 days were not significantly
improved compared with the results of previous studies.
The possible reason could be insufficient radiotherapy and
chemotherapy doses. Therefore, the effect of topotecan
combined with concurrent radiation therapy to treat
brain metastases from lung cancer has not yet been
thoroughly assessed.
Whole-brain irradiation plus local conformal boost can
improve local tumour control, but there is no conclusive
evidence showing that it improves survival. The applica-
tion of concurrent chemotherapy drugs can treat extracra-
nial lesions and further improve the local control of
intracranial lesions. Consequently, whole-brain irradiation
plus 3-D conformal boost radiotherapy with concurrent
chemotherapy would theoretically improve survival. To
our knowledge, there are no reports on whole-brain irradi-
ation plus 3-D conformal boost radiotherapy with concur-
rent chemotherapy to treat intracranial metastasis from
lung cancer. Although the maximum tolerated dose of
topotecan had been reported [14,15,24], we considered
that the maximum tolerated dose for the western popula-
tion may not be applicable to the Asian population due to
physical differences between the populations, and thisconsideration was also based on our previous study results
on concurrent chemotherapy and radiotherapy [25,26].
Therefore, we conducted a phase I clinical study using
whole-brain irradiation plus 3-D conformal boost, com-
bined with weekly topotecan chemotherapy. The patients
with brain metastases from lung cancer in this study had ≤
3 intracranial metastases that were ≥ 2 cm in diameter.
We found that the maximum tolerated dose of topotecan
for Chinese patients was 1.75 mg/m2/w [16]. Based on
this result, we performed this phase II clinical study.
Our study met its primary endpoint, which was that con-
current chemoradiotherapy significantly improved PFS for
patients with brain metastases from lung cancer. Compared
with the radiotherapy-alone group, concurrent conformal
radiotherapy significantly improved intracranial lesion con-
trol. The 1- and 2-year intracranial lesion local control rates
of the concurrent chemoradiotherapy and radiotherapy-
alone groups were 75.9% and 65.2% and 41.6% and 31.2%
(χ2 = 3.892, p = 0.049), respectively. No difference in overall
survival (OS) was found between the two groups, with the
possible reason being that CRT failed to significantly reduce
extracranial lesion progress. No difference in the extracra-
nial lesion control rate was found between the two groups
(χ2 = 0.610, p = 0.435), and the main cause of death in pa-
tients in both groups was distant metastasis. Compared
Figure 7 For non-small cell lung cancer, the MST and the 1- and 2-year survival rates of the two groups were 10 months, 33.8%,
16.9% and 8 months, 26.3%, 9.9%, respectively.
Table 2 Comparison of side effects of two groups (case)
Adverse event Grade CRT group RT group χ2 p
Leukopenia I 16 13 1.599 0.206
II 8 6
III 2 0
Neutropenia I 15 12 1.560 0.212
II 7 5
III 2 0
Thrombocytopenia I 4 1 2.492 0.114
III 1 0
Anemia I 5 3 0.140 0.709
Nausea and vomiting I 8 5 1.418 0.234
II 4 2
Anorexia I 10 8 0.140 0.709
Radiation dermatitis I 6 5 0.106 0.744
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OS, the NSCLC in the CRT group obtained an average
MST of 10 months and a 1-year OS of 33.8%. These results
are comparable with the therapeutic outcomes of whole-
brain irradiation combined with concurrent temozolomide
(TMZ) chemotherapy and targeted therapy, which pro-
duced MSTs of 6.3 and 4.0 months and 1-year OS rates of
20.0% and 37.5%, respectively [27]. The comparable re-
sults confirmed the validity of the treatment plan in our
research. Our study showed that the application of
localised boost irradiation technology and concurrent
topotecan chemotherapy achieved better local control
of intracranial lesions but did not improve the extracra-
nial lesion control rate. Arrieta et al. [28] reported that
whole-brain irradiation with concurrent chemotherapy
and chest chemoradiotherapy can be applied to strengthen
the control of extracranial lesions for lung cancer patients
with brain metastases without metastasis in other organs.
In this small retrospective study, the treatment plan pro-
vided very good efficacy, with PFS and OS of 8.43 ±
1.5 months and 31.8 ± 15.8 months, and the 1- and 2-year
PFS and OS were 39.5% and 24.7% and 71.1% and 60.2%,
respectively. The study also confirmed the importance of
strong concurrent chemoradiotherapy on extracranial le-
sions to improve lesion control rate.How to effectively control extracranial lesions is the dir-
ection of the future research. The combination of radio-
therapy and two-drug chemotherapy should theoretically
reduce the possibility of distant metastasis. Tang et al. [29]
applied docetaxel and cisplatin concurrent with whole-
brain radiation therapy and found that 1-year survival rate
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significantly higher than the 30% survival rate in the
radiotherapy-alone group. In recent years, the targeted
drugs gefitinib and erlotinib showed good efficacy in the
treatment of NSCLC [30] and some studies showed effi-
cacy for brain metastases from lung cancer [31-34]. In
the future, whole-brain irradiation with concurrent
targeted therapy could be used to improve the systemic
tumour control rate, thereby improving overall survival.
Conclusion
In summary, whole-brain irradiation plus conformal boost
irradiation with concurrent topotecan chemotherapy for
brain metastasis from lung cancer resulted in good PFS
and the intracranial lesion control rate, and showed good
tolerance. We recommend this treatment plan for a phase
III clinical trial to further investigate long-term efficacy.
Whole-brain irradiation plus conformal boost combined
with two-drug chemotherapy regimen or targeted drug
may be a potential treatment plan to improve the efficacy
of treatment for brain metastasis from lung cancer.
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